8-Carboxamidocyclazocine: a long-acting, novel benzomorphan.

  title={8-Carboxamidocyclazocine: a long-acting, novel benzomorphan.},
  author={Jean M. Bidlack and Dana J. Cohen and Jay P. McLaughlin and Rongliang Lou and Y Ye and Mark P. Wentland},
  journal={The Journal of pharmacology and experimental therapeutics},
  volume={302 1},
To obtain benzomorphans with a longer duration of action that may be potential therapeutics for treating cocaine abuse, 8-carboxamidocyclazocine was synthesized. The pharmacological properties of 8-carboxamidocyclazocine were compared with the parent compound cyclazocine. Changing the 8-hydroxyl group on cyclazocine to an 8-carboxamido group resulted in only a 2-fold decrease in the affinity of the compound for the kappa-receptor, and no change in the affinity for the mu-opioid receptor, with… 

Figures and Tables from this paper

Characterization of CM-398, a Novel Selective Sigma-2 Receptor Ligand, as a Potential Therapeutic for Neuropathic Pain
Results demonstrate the S2R selective antagonist CM-398 produces antinociception and anti-allodynia with fewer liabilities than established therapeutics, adding to emerging data suggesting possible mediation of nociceptive testing by sigma-2 receptors, and the development of S1R ligands as potential treatments for chronic pain.
Characterization of Sigma 1 Receptor Antagonist CM-304 and Its Analog, AZ-66: Novel Therapeutics Against Allodynia and Induced Pain
Results demonstrate the S1R selective antagonist CM-304 produces antinociception and anti-allodynia with fewer liabilities than established therapeutics, supporting the use of S 1R antagonists as potential treatments for chronic pain.
Orvinols with Mixed Kappa/Mu Opioid Receptor Agonist Activity
It is shown that a predictive model for efficacy at KOR can be derived, with efficacy being controlled by the length of the group attached to C20 and by the introduction of branching into the side chain.
Kappa-opioid receptor ligands
A review of the patent literature covering the years 2000 – 2003 will focus on activities of a number of new classes of KOR antagonist being discovered using rational drug design techniques and describe the therapeutic potential of these compounds.
Examination of the Novel Sigma-1 Receptor Antagonist, SI 1/28, for Antinociceptive and Anti-allodynic Efficacy against Multiple Types of Nociception with Fewer Liabilities of Use
SI 1/28 proved efficacious in the treatment of acute inflammatory pain and chronic neuropathy without liabilities at therapeutic doses, supporting the development of S1R antagonists as therapeutics for chronic pain.
LP1 and LP2: Dual-Target MOPr/DOPr Ligands as Drug Candidates for Persistent Pain Relief
The structure–activity relationships and the pharmacological fingerprint of LP1 and LP2 compounds as suitable drug candidates for persistent pain relief is described.


8-Carboxamidocyclazocine analogues: redefining the structure-activity relationships of 2,6-methano-3-benzazocines.
Synthesis and opioid receptor affinity of morphinan and benzomorphan derivatives: mixed kappa agonists and mu agonists/antagonists as potential pharmacotherapeutics for cocaine dependence.
Binding experiments demonstrated that the cyclobutyl analogue 3b of cyclorphan (3a) had a high affinity for mu, delta, and kappa opioid receptors in guinea pig brain membranes, and both 3a and 3b had comparable kappa agonist properties.
Cyclazocine: comparison to hydromorphone and interaction with cocaine
This study is suggestive but not strongly supportive for the use of kappa-opiate drugs to diminish acute effects of cocaine administration or for theUse of these kappa agonists in drug abuse treatment applications.
Partial Opioids: Medications for the Treatment of Pain and Drug Abuse
Pentazocine and cyclazocines are two benzomorphans that were synthesized by the late Sydney Archer in 1962 as part of an effort to develop analgesics with little or no abuse potential.
8-Aminocyclazocine analogues: synthesis and structure-activity relationships.
Naloxone reduces the neurochemical and behavioral effects of amphetamine but not those of cocaine.
Naltrexone–Buprenorphine Interactions: Effects on Cocaine Self-Administration
It is suggested that naltrexone antagonizes the partial mu agonist component of buprenorphine, which may be important for bup Renorphine's effects on cocaine self-administration and compromise its effectiveness for treatment of dual dependence on cocaine and opiates.
U69593, a kappa-opioid agonist, decreases cocaine self-administration and decreases cocaine-produced drug-seeking
U69593 attenuates cocaine self-administration and the reinstatement of drug-taking behavior which occurs in response to experimenter-administered cocaine.
Opioid peptides selective for receptor types modulate cocaine-induced behavioral responses in mice.
The results suggest that the activation of mu- and kappa-opioid receptors inhibits cocaine-induced behavior, while that of delta-opIOid receptors enhances the behavior.
Synthesis and pharmacology of 8-amino-3-(cyclopropylmethyl)-1,2,3,4,5,6-hexahydro-cis-6,11-dimethyl-2,6-methano-3-benzazocine and related compounds.
The little compound 1a has been prepared and was found to be a strong, orally active agonist with narcotic--antagonist properties. 1a was prepared by two independent routes: (1) nitration of